Customize your JAMA Network experience by selecting one or more topics from the list below.
Chien H, Kao Yang Y, Bai JPF. Trastuzumab-Related Cardiotoxic Effects in Taiwanese Women: A Nationwide Cohort Study. JAMA Oncol. 2016;2(10):1317–1325. doi:https://doi.org/10.1001/jamaoncol.2016.1269
What is the incidence and risk of heart failure (HF) and/or cardiomyopathy (CM) among Asian trastuzumab users with breast cancer?
In this nationwide cohort study of Taiwanese women with incident breast cancer the crude incidence of HF and/or CM was significantly higher in trastuzumab users compared with nonusers.
The findings provide critical trastuzumab cardiac safety information for Asian patients with breast cancer.
Trastuzumab is an essential medicine per the World Health Organization Model List, but its cardiac safety information in Asian women is limited.
To estimate the rate and the risk of heart failure (HF) and/or cardiomyopathy (CM) in Asian women undergoing trastuzumab treatment.
This cohort study used the Taiwanese National Health Insurance Research Database (NHIRD), a nationwide claim database covering more than 99% of the entire Taiwanese population, to identify 23 006 women with incident breast cancer (BC) who received chemotherapy from 2006 to 2009. We grouped women per their initial treatment regimens and found 1066 new trastuzumab users. We matched trastuzumab users with nonusers by year of BC diagnosis and propensity score (PS) with the caliper widths at 0.25 standard deviation of PS (up to 4 nonusers per trastuzumab user). The study lasted from January 2006 to December 2013 with a median follow-up of 5.29 years and a landmark design to avoid immortal time bias.
Main Outcomes and Measures
To estimate HF and/or CM rates and time to HF and/or CM, we employed a cause-specific hazard model. Trastuzumab exposure was a time-dependent variable, while cumulative courses of chemotherapy agents with known cardiotoxic effects (including anthracyclines, taxanes, and cyclophosphamide) were defined as time-dependent covariates in the analysis model. We also performed 6 sensitivity analyses.
In this cohort of 23 006 women (mean age, 50.99 years), the crude incidence of HF and/or CM was 4.03% in trastuzumab users and 2.88% in nonusers. The median time to HF and/or CM was 456 days in trastuzumab users and 966 days in nonusers. The 1-year cumulative hazard ratio was 1.86 (95% CI, 1.08-3.19). The sensitivity analyses yielded similar results.
Conclusions and Relevance
Compared with the published results, the trastuzumab-related HF and/or CM rate was 5-fold lower in Taiwanese women with breast cancer. Nonetheless, our cohort had a similar trastuzumab-related HF and/or CM risk. Our study provides critical cardiac safety information of trastuzumab for Asian women with BC under current treatment guidelines and label information.
Create a personal account or sign in to: